Overall The Fred & Pamela Buffett Cancer Center (Buffett Cancer Center or FPBCC) at the University of Nebraska Medical Center is committed to developing new strategies for the treatment and prevention of cancer through innovative interdisciplinary research, premier educational programs, the highest quality patient care, and outreach to underserved populations. The Buffett Cancer Center is dedicated to reducing the burden of cancer through interdisciplinary translational cancer research leading to new therapies for cancer treatment as well as enhancing the well-being of cancer survivors. As the only NCI-designated Cancer Center in Nebraska, we are very sensitive to the needs of the underserved populations in our catchment area (across the state of Nebraska and western Iowa), including women, minorities and children as well as the medically underserved rural residents in our region. The 84 members of the Buffett Cancer Center are actively involved in the interdisciplinary FPBCC Research Programs including the Molecular and Biochemical Etiology Program (MBEP), the Cancer Genes and Molecular Regulation Program (CGMR), and the Gastrointestinal Cancer Program (GICP). The FBPCC is a matrix with Members in each of the Colleges and Institutes at UNMC, as well as Members at the University of Nebraska - Lincoln and the University of Nebraska - Omaha. The FPBCC Director also leads the Eppley Cancer Institute, with 30 tenure/tenure-leading faculty appointments. The FPBCC Director reports directly to the Chancellor of UNMC and serves on the UNMC Chancellor's Council and the Nebraska Medicine's Senior Leadership Team, the two most senior and responsible cabinets of the the academic and the clinical enterprise. A new $323 M Buffett Cancer Center (625,000 gsf) will open in 2017 integrating cancer research and care in one facility and provide ample room FPBCC growth. Since the last review, the FPBCC enhanced interdisciplinary research collaborations by providing support for recruitment of 30 new Members (including the co-leaders of the GICP and the Director of the Bioinformatics Shared Resource), for enhancements to shared research facilities, and for pilot funding for collaborative multidisciplinary research projects. The FPBCC has a robust track record of transdisciplinary cancer research and strong evidence of collaborations bridging all of the Research Programs. Buffett Cancer Center research has resulted in 1409 publications of which 23% are inter-programmatic collaborations, 23% are intra-programmatic collaborations and 9% are both. FPBCC externally funded cancer research portfolio which currently exceeds $34.3 M annually in peer-reviewed support (> 46% NCI) demonstrates university-wide transdisciplinary cancer research collaborations by Buffett Cancer Center Members focused on resolving cancer-related problems.

Public Health Relevance

Overall The mission of the Fred and Pamela Buffett Cancer Center (FPBCC), formerly known as the UNMC Eppley Cancer Center, is to understand, prevent and cure cancer in Nebraska through premier educational programs, innovative research, the highest quality patient care, and outreach to underserved populations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Program Officer
Ogunbiyi, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Nebraska Medical Center
Schools of Medicine
United States
Zip Code
Barkeer, Srikanth; Chugh, Seema; Karmakar, Saswati et al. (2018) Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells. BMC Cancer 18:1157
Cserhati, Matyas F; Mooter, Mary-Ellen; Peterson, Lauren et al. (2018) Motifome comparison between modern human, Neanderthal and Denisovan. BMC Genomics 19:472
Napon, Geoffroy; Dafferner, Alicia J; Saxena, Ashima et al. (2018) Identification of Carboxylesterase, Butyrylcholinesterase, Acetylcholinesterase, Paraoxonase, and Albumin Pseudoesterase in Guinea Pig Plasma through Nondenaturing Gel Electrophoresis. Comp Med 68:367-374
Luan, Haitao; Mohapatra, Bhopal; Bielecki, Timothy A et al. (2018) Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program. Cancer Res 78:2524-2535
Rana, Sandeep; Sonawane, Yogesh A; Taylor, Margaret A et al. (2018) Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy. Bioorg Med Chem Lett 28:3736-3740
Azadmanesh, Jahaun; Borgstahl, Gloria E O (2018) A Review of the Catalytic Mechanism of Human Manganese Superoxide Dismutase. Antioxidants (Basel) 7:
Haney, Staci L; Chhonker, Yashpal S; Varney, Michelle L et al. (2018) Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor. Invest New Drugs 36:810-818
Chhonker, Yashpal S; Haney, Staci L; Matthiesen, Robert A et al. (2018) Quantitative determination of a potent geranylgeranyl diphosphate synthase inhibitor using LC-MS/MS: Derivatization and application. J Pharm Biomed Anal 153:22-28
Lockridge, Oksana; David, Emilie; Schopfer, Lawrence M et al. (2018) Purification of recombinant human butyrylcholinesterase on Hupresin®. J Chromatogr B Analyt Technol Biomed Life Sci 1102-1103:109-115
Saxena, Sugandha; Hayashi, Yuri; Wu, Lingyun et al. (2018) Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis. Oncotarget 9:5931-5943

Showing the most recent 10 out of 1372 publications